The Company also highlights the potential of its melanoma franchise building on KIMMTRAK’s performance and reveals details of IMC-U120AI (CD1a x PD1), its first non-HLA restricted candidate.

Immunocore Holdings plc announced its strategic priorities for 2025, focusing on expanding access to its melanoma treatment, KIMMTRAK (tebentafusp), and advancing its clinical pipeline in oncology ...

Immunocore now has approval on both sides of the Atlantic for Kimmtrak – the first cancer therapeutic based on T cell receptor (TCR) technology – after getting a green light from the European ...